25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
Our Virtual Regional Compliance Conferences provide updates on the latest news in regulatory require...
Read More >
On September 26, 2019, Justice Saliann Scarpulla of the New York State Supreme Court, County of New ...
Read More >
On February 1, 2021, the Federal Trade Commission (FTC) announced revised notification thresholds fo...
Read More >
The Americans with Disabilities Act prohibits discrimination in employment against persons who are d...
Read More >
Seyfarth Synopsis: Recently the U.S. House of Representatives passed a bill with bipartisan support ...
Read More >
Below is the City of Boston’s Press Release suspending all regular activity at construction sites i...
Read More >